- Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area.
- Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.
- Genscript USA, a division of China-headquartered Genscript Biotech, reported its cPass SARS-CoV-2 Neutralization Antibody Detection Kit was approved in the US under Emergency Use rules.
For further details see:
Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO